Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
acromegaly | — | D000172 | — |
adenoma | — | D000236 | — |
diarrhea | HP_0002014 | D003967 | R19.7 |
pancreatic neoplasms | EFO_0003860 | D010190 | C25 |
pituitary neoplasms | — | D010911 | — |
Expiration | Code | ||
---|---|---|---|
OCTREOTIDE ACETATE, MYCAPSSA, AMRYT | |||
2023-06-26 | NP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Acromegaly | D000172 | — | — | 5 | 11 | 16 | 17 | 9 | 57 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 10 | 24 | 10 | 3 | 7 | 50 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | 3 | 1 | 4 | 4 | 11 |
Neoplasms | D009369 | — | C80 | 2 | 5 | 3 | 2 | — | 11 |
Diarrhea | D003967 | HP_0002014 | R19.7 | — | 2 | 3 | 1 | 3 | 9 |
Obesity | D009765 | EFO_0001073 | E66.9 | 2 | 1 | — | 3 | 3 | 9 |
Hepatorenal syndrome | D006530 | — | K76.7 | — | 4 | 2 | 1 | 2 | 7 |
Esophageal and gastric varices | D004932 | EFO_0009545 | I85 | 1 | 1 | — | 3 | 1 | 5 |
Congenital hyperinsulinism | D044903 | — | — | 1 | 1 | — | 1 | — | 3 |
Ascites | D001201 | HP_0001541 | R18 | — | 2 | 1 | 1 | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoid tumor | D002276 | — | D3A.00 | 4 | 5 | 4 | — | — | 11 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 5 | 1 | — | 1 | 8 |
Prostatic neoplasms | D011471 | — | C61 | 1 | 3 | 1 | — | — | 5 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 2 | — | 2 | 5 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 2 | 3 | — | 1 | 5 |
Colorectal neoplasms | D015179 | — | — | — | 1 | 4 | — | — | 5 |
Autosomal dominant polycystic kidney | D016891 | EFO_1001496 | Q61.2 | — | 2 | 3 | — | 1 | 5 |
Gastro-enteropancreatic neuroendocrine tumor | — | — | — | 1 | — | 3 | — | — | 4 |
Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | 4 | — | — | 4 |
Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | — | — | 1 | — | 2 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuroendocrine carcinoma | D018278 | — | — | 1 | 6 | — | — | — | 7 |
Neuroblastoma | D009447 | EFO_0000621 | — | 3 | 6 | — | — | — | 7 |
Meningioma | D008579 | EFO_0003098 | D32.9 | 2 | 3 | — | — | 1 | 6 |
Medulloblastoma | D008527 | — | — | 1 | 4 | — | — | 1 | 5 |
Islet cell adenoma | D007516 | EFO_0007331 | D13.7 | 2 | 3 | — | — | — | 5 |
Esophageal neoplasms | D004938 | — | C15 | — | 1 | — | — | 4 | 5 |
Pheochromocytoma | D010673 | — | — | 2 | 2 | — | — | — | 4 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 2 | — | — | 2 | 4 |
Acute kidney injury | D058186 | HP_0001919 | N17 | — | 1 | — | — | 2 | 3 |
Paraganglioma | D010235 | — | — | 2 | 2 | — | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
Insulin resistance | D007333 | HP_0000855 | E88.819 | 3 | — | — | — | 2 | 5 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 2 | — | — | — | 1 | 3 |
Central nervous system neoplasms | D016543 | — | — | 2 | — | — | — | — | 2 |
Prediabetic state | D011236 | EFO_1001121 | R73.03 | 2 | — | — | — | — | 2 |
Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
Orthostatic hypotension | D007024 | — | I95.1 | 1 | — | — | — | — | 1 |
Von hippel-lindau disease | D006623 | — | Q85.83 | 1 | — | — | — | — | 1 |
Multiple endocrine neoplasia type 1 | D018761 | — | E31.21 | 1 | — | — | — | — | 1 |
Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 2 | 2 |
Weight loss | D015431 | HP_0001824 | — | — | — | — | — | 2 | 2 |
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 2 | 2 |
Myocarditis | D009205 | — | I51.4 | — | — | — | — | 1 | 1 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | — | 1 | 1 |
Glioma | D005910 | EFO_0000520 | — | — | — | — | — | 1 | 1 |
Gliosarcoma | D018316 | — | — | — | — | — | — | 1 | 1 |
Acoustic neuroma | D009464 | HP_0009588 | — | — | — | — | — | 1 | 1 |
Drug common name | Octreotide |
INN | octreotide |
Description | Octreotide, sold under the brand name Sandostatin among others, is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 by the chemist Wilfried Bauer, and binds predominantly to the somatostatin receptors SSTR2 and SSTR5.
|
Classification | Protein |
Drug class | peptides: inhibition of growth hormone release |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O |
PDB | — |
CAS-ID | 83150-76-9 |
RxCUI | 7617 |
ChEMBL ID | CHEMBL1680 |
ChEBI ID | — |
PubChem CID | 448601 |
DrugBank | DB00104 |
UNII ID | RWM8CCW8GP (ChemIDplus, GSRS) |